BRPI1008023A2 - forma de dosagem sólida - Google Patents

forma de dosagem sólida

Info

Publication number: BRPI1008023A2
Authority: BR; Brazil
Prior art keywords: dosage form; solid dosage; solid; dosage
Prior art date: 2009-02-13

Application number

BRPI1008023A

Other languages

English (en)

Inventor

Colin J Meyer

Jiang Zhang

Original Assignee

Reata Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2016-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008023(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-12 Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc

2016-03-15 Publication of BRPI1008023A2 publication Critical patent/BRPI1008023A2/pt

2019-12-31 Publication of BRPI1008023B1 publication Critical patent/BRPI1008023B1/pt

2023-04-11 Publication of BRPI1008023B8 publication Critical patent/BRPI1008023B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1008023A 2009-02-13 2010-02-12 Forma de dosagem sólida BRPI1008023B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15260809P	2009-02-13	2009-02-13
PCT/US2010/024127 WO2010093944A2 (en)	2009-02-13	2010-02-12	Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (3)

Publication Number	Publication Date
BRPI1008023A2 true BRPI1008023A2 (pt)	2016-03-15
BRPI1008023B1 BRPI1008023B1 (pt)	2019-12-31
BRPI1008023B8 BRPI1008023B8 (pt)	2023-04-11

Family

ID=42335073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008023A BRPI1008023B8 (pt)	2009-02-13	2010-02-12	Forma de dosagem sólida

Country Status (30)

Country	Link
US (2)	US8747901B2 (pt)
EP (2)	EP3254675B1 (pt)
JP (1)	JP5775464B2 (pt)
KR (2)	KR20140016441A (pt)
CN (2)	CN102387789A (pt)
AU (1)	AU2010213594B2 (pt)
BR (1)	BRPI1008023B8 (pt)
CA (1)	CA2752048C (pt)
CO (1)	CO6361904A2 (pt)
CY (2)	CY1119595T1 (pt)
DK (2)	DK2395979T3 (pt)
EA (1)	EA023652B1 (pt)
ES (2)	ES2646816T3 (pt)
HK (1)	HK1220130A1 (pt)
HR (2)	HRP20171639T1 (pt)
HU (2)	HUE035013T2 (pt)
IL (1)	IL214258A (pt)
LT (2)	LT3254675T (pt)
MX (1)	MX2011008344A (pt)
MY (1)	MY173715A (pt)
NO (1)	NO2395979T3 (pt)
NZ (1)	NZ594488A (pt)
PL (2)	PL2395979T3 (pt)
PT (2)	PT2395979T (pt)
SG (1)	SG173601A1 (pt)
SI (2)	SI3254675T1 (pt)
SM (2)	SMT201700527T1 (pt)
TR (1)	TR201909743T4 (pt)
WO (1)	WO2010093944A2 (pt)
ZA (1)	ZA201105630B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
CN104739841B (zh)	2008-01-11	2018-06-01	里亚塔医药公司	合成三萜类化合物及用以治病之方法
BRPI0911105B1 (pt)	2008-04-18	2022-11-08	Reata Pharmaceuticals, Inc	Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
US8124799B2 (en)	2008-04-18	2012-02-28	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CA2721666C (en)	2008-04-18	2017-05-23	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
TWI442925B (zh)	2008-04-18	2014-07-01	Reata Pharmaceuticals Inc	抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物
CA2731650A1 (en)	2008-07-22	2010-01-28	Tadashi Honda	Monocyclic cyanoenones and methods of use thereof
JP5775464B2 (ja)	2009-02-13	2015-09-09	リアタファーマシューティカルズ，インク	非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
MY163031A (en)	2010-04-12	2017-07-31	Reata Pharmaceuticals Inc	Method of treating obesity using antioxidant inflammation modulators
ME02973B (me)	2010-12-17	2018-07-20	Reata Pharmaceuticals Inc	Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
UY33946A (es)	2011-03-11	2012-08-31	Reata Pharmaceuticals Inc	Derivados de c4-monometil triterpenoides y sus métodos de uso
CN103156861B (zh) *	2011-12-08	2015-11-25	陈丽梅	齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
PT3444261T (pt)	2012-04-27	2021-03-12	Reata Pharmaceuticals Inc	Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI630212B (zh)	2012-09-10	2018-07-21	瑞塔醫藥有限責任公司	丁香油素（ｏｌｅａｎｏｌｉｃａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法
US9278912B2 (en)	2012-09-10	2016-03-08	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
UY39092A (es)	2013-04-24	2021-03-26	Abbvie Inc	Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
CA2921386A1 (en)	2013-08-23	2015-02-26	Reata Pharmaceuticals, Inc.	Methods of treating and preventing renal disease using bardoxolone methyl or analogs thereof
EP3212195A4 (en)	2014-10-31	2018-06-06	The Regents of The University of California	Compositions and methods for treating hiv-associated cognitive dysfunction
WO2016130927A1 (en)	2015-02-12	2016-08-18	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant iflammation modulators
AU2016326704B2 (en)	2015-09-23	2021-01-28	Reata Pharmaceuticals, Inc.	C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
BR112019009256A2 (pt)	2016-11-08	2019-07-16	Reata Pharmaceuticals Inc	métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11427533B2 (en)	2017-07-13	2022-08-30	Pliva Hrvatska D.O.O.	Crystalline polymorphs of bardoxolone methyl
WO2019193488A1 (en)	2018-04-06	2019-10-10	Capsugel Belgium Nv	Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CA3103726A1 (en)	2018-06-15	2019-12-19	Reata Pharmaceuticals, Inc.	Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
WO2019246461A1 (en)	2018-06-20	2019-12-26	Reata Pharmaceuticals, Inc.	Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR20210096162A (ko)	2018-11-27	2021-08-04	쿄와 기린 가부시키가이샤	의약 조성물
AU2020316351A1 (en)	2019-07-19	2022-02-17	Reata Pharmaceuticals, Inc.	C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
CA3177913A1 (en)	2020-05-09	2021-11-18	Deborah FERGUSON	Methods of treating covid-19 using bardoxolone methyl or analogs thereof
WO2022126129A1 (en)	2020-12-11	2022-06-16	Reata Pharmaceuticals, Inc.	Synthetic triterpenoids for use in therapy
CN114558019A (zh) *	2022-03-26	2022-05-31	中国科学院昆明动物研究所	一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US7435755B2 (en) *	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
JP2008110962A (ja) *	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) *	2006-10-30	2009-08-19	ミツミ電機株式会社	カメラモジュール
WO2008111497A1 (ja) *	2007-03-08	2008-09-18	Santen Pharmaceutical Co., Ltd.	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) *	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
CN104739841B (zh) *	2008-01-11	2018-06-01	里亚塔医药公司	合成三萜类化合物及用以治病之方法
JP5775464B2 (ja)	2009-02-13	2015-09-09	リアタファーマシューティカルズ，インク	非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物

2010
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en not_active Ceased
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown

Also Published As

Publication number	Publication date
AU2010213594A1 (en)	2011-08-18
CN102387789A (zh)	2012-03-21
ZA201105630B (en)	2012-04-25
HRP20171639T1 (hr)	2017-12-15
BRPI1008023B8 (pt)	2023-04-11
HUE044005T2 (hu)	2019-09-30
SG173601A1 (en)	2011-09-29
WO2010093944A2 (en)	2010-08-19
US20140235711A1 (en)	2014-08-21
ES2646816T3 (es)	2017-12-18
KR20140016441A (ko)	2014-02-07
PL3254675T3 (pl)	2019-09-30
BRPI1008023B1 (pt)	2019-12-31
NO2395979T3 (pt)	2018-01-20
CO6361904A2 (es)	2012-01-20
SI3254675T1 (sl)	2019-08-30
EP2395979A2 (en)	2011-12-21
WO2010093944A3 (en)	2011-08-11
KR101483203B1 (ko)	2015-01-15
IL214258A (en)	2017-06-29
DK2395979T3 (da)	2017-11-27
JP5775464B2 (ja)	2015-09-09
EA023652B1 (ru)	2016-06-30
PT3254675T (pt)	2019-06-14
LT3254675T (lt)	2019-06-25
LT2395979T (lt)	2017-12-11
TR201909743T4 (tr)	2019-07-22
PL2395979T3 (pl)	2018-02-28
AU2010213594B2 (en)	2013-11-14
CY1122066T1 (el)	2020-11-25
HK1220130A1 (zh)	2017-04-28
SMT201900432T1 (it)	2019-09-09
JP2012518008A (ja)	2012-08-09
CA2752048A1 (en)	2010-08-19
HRP20191092T1 (hr)	2019-11-29
EP3254675B1 (en)	2019-05-15
HUE035013T2 (en)	2018-05-02
ES2731601T3 (es)	2019-11-18
US20120022156A1 (en)	2012-01-26
US8747901B2 (en)	2014-06-10
SMT201700527T1 (it)	2018-01-11
CA2752048C (en)	2014-11-25
EP3254675A1 (en)	2017-12-13
EA201190092A1 (ru)	2012-02-28
NZ594488A (en)	2013-10-25
SI2395979T1 (sl)	2017-12-29
CY1119595T1 (el)	2018-03-07
US9155721B2 (en)	2015-10-13
IL214258A0 (en)	2011-09-27
KR20110118721A (ko)	2011-10-31
CN105232471A (zh)	2016-01-13
DK3254675T3 (da)	2019-06-24
MY173715A (en)	2020-02-18
MX2011008344A (es)	2011-09-29
EP2395979B1 (en)	2017-08-23
PT2395979T (pt)	2017-11-16

Publication	Publication Date	Title
BRPI1008023A2 (pt)	2016-03-15	forma de dosagem sólida
BR112013014361A2 (pt)	2016-09-27	forma de dosagem
DK2427449T3 (da)	2013-04-22	Vinylindazolylforbindelser
BR112012006859A2 (pt)	2019-09-24	compostos
DK2414015T3 (da)	2021-12-06	Laryngoskopsystem
DE112010004215A5 (de)	2012-08-23	Hydrostataktor
EP2469625A4 (en)	2015-11-04	OMNIBUS BAR
EP2491340A4 (en)	2014-12-24	TELEMETRY PHOTOGRAPHIC APPARATUS
EP2509489A4 (en)	2015-04-01	SPRINKLER FOR EARLY HEEL REMOVAL
EP2440486A4 (en)	2013-09-25	CABLE RETRACTION SYSTEM
BRPI1005525A2 (pt)	2016-02-23	compostos de azaazuleno
DK2430035T3 (da)	2013-05-27	Uracylspipooxetannukleosider
BRPI1014968A2 (pt)	2016-12-13	subalargador
DE112010002728A5 (de)	2012-06-21	Turboinhalator
DE112010004249A5 (de)	2012-11-29	Spindelaktor
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
EP2402744A4 (en)	2015-05-13	CARBURATION DETECTION METHOD
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
EP2446176A4 (en)	2016-12-14	CYLINDER SEAL
EP2409976A4 (en)	2012-09-19	GLYCINE TRANSPORTER INHIBITOR
BR112012031102A2 (pt)	2015-09-22	forma de dosagem oral sólida
DK2483126T3 (da)	2015-06-22	Skinnekøretøj
DE112010004865T8 (de)	2013-01-24	Lamellennassreibkupplung
BRPI0807882A2 (pt)	2014-06-17	Forma de dosagem

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-10-02	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-07-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-19	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-12-31	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS.
2023-04-11	B25A	Requested transfer of rights approved	Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)